Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
RLMD
$4.26
$
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Next Earnings
2026-02-25
Beta
0.771
Average Volume
Market Cap
Last Dividend
CIK
0001553643
ISIN
US75955J4022
CUSIP
75955J402
CEO
Sergio Traversa
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
17
IPO Date
2014-06-20
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9% – Here’s Why | Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) traded up 6.9% on Thursday. The company traded as high as $4.47 and last traded at $4.36. Approximately 1,939,623 shares were traded during mid-day trading, an increase of 257% from the average session volume of 543,317 shares. The stock had previously closed at $4.08. Wall Street | Defense World | 2026-02-20 04:48:53 |
| Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $9.00 | Shares of Relmada Therapeutics, Inc. (NASDAQ: RLMD - Get Free Report) have received a consensus rating of "Hold" from the five ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to | Defense World | 2026-02-01 01:11:01 |
| Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications | FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the registrational development pathway for NDV-01 in 2nd-line refractory, high-grade BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) -- one of the highest-risk and most treatment-resistant NMIBC populations -- and in intermediate risk NMIBC in the adjuvant setting, where there are currently no approved therapies. | GlobeNewsWire | 2026-01-12 07:00:00 |
| Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) | Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends. Volatility and Risk Relmada Therapeutics has a | Defense World | 2026-01-05 02:34:53 |
| Here Are Monday’s Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie’s Bargain Outlet, Sealed Air, Volaris, and More | Pre-Market Stock Futures: Futures are trading higher as we get ready to start a holiday-shortened trading week after an outstanding triple-witching Friday rally that may have kicked the "Santa Claus" rally into high gear. All of the major indices, including the Russell 2000, finished the day higher, and Oracle Corp. (NYSE: ORCL), which has been... Here Are Monday's Top Wall Street Analyst Research Calls: BlackSky Technology, Cummins, Lamb Watson, Ollie's Bargain Outlet, Sealed Air, Volaris, and More. | 247 Wallst | 2025-12-22 08:12:30 |
| Comparing BeOne Medicines (NASDAQ:ONC) & Relmada Therapeutics (NASDAQ:RLMD) | BeOne Medicines (NASDAQ: ONC - Get Free Report) and Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, institutional ownership and risk. Institutional and Insider Ownership 48.6% of BeOne Medicines | Defense World | 2025-12-11 02:00:51 |
| Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology | Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, representing about 80% of new NMIBC cases every year, or about 54,000 people in the United States CORAL GABLES, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that the previously disclosed 6-month follow-up data from the ongoing Phase 2 study of NDV-01, a sustained release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce), in development for non-muscle invasive bladder cancer (NMIBC) will be presented in a poster at the Society of Urologic Oncology 26th Annual Meeting (SUO 2025). | GlobeNewsWire | 2025-12-03 07:30:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G | 2026-02-12 | 2026-02-12 | View Filing |
| SC 13G | 2026-02-06 | 2026-02-06 | View Filing |
| 424B5 | 2026-01-30 | 2026-01-30 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 4 | 2025-12-16 | 2025-12-16 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| SC 13G | 2025-11-14 | 2025-11-14 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-11-05 | 2025-11-04 | View Filing |
| 424B5 | 2025-11-05 | 2025-11-04 | View Filing |
| FWP | 2025-11-04 | 2025-11-04 | View Filing |
| 8-K | 2025-11-04 | 2025-11-04 | View Filing |
| 8-K | 2025-09-17 | 2025-09-17 | View Filing |
| 8-K | 2025-09-16 | 2025-09-16 | View Filing |
| 8-K | 2025-09-10 | 2025-09-10 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| 4 | 2025-08-28 | 2025-08-28 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-07-23 | 2025-07-23 | View Filing |
| 8-K | 2025-07-10 | 2025-07-10 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 4 | 2025-06-30 | 2025-06-30 | View Filing |
| 8-K | 2025-06-18 | 2025-06-17 | View Filing |
| S-8 | 2025-06-13 | 2025-06-12 | View Filing |
| 8-K | 2025-05-27 | 2025-05-27 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 10-Q | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| SC 13G | 2025-05-01 | 2025-05-01 | View Filing |
| 424B5 | 2025-04-28 | 2025-04-28 | View Filing |
| 8-K | 2025-04-28 | 2025-04-28 | View Filing |
| DEFA14A | 2025-04-11 | 2025-04-11 | View Filing |
| DEF 14A | 2025-04-11 | 2025-04-11 | View Filing |
| 8-K | 2025-03-27 | 2025-03-27 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 8-K | 2025-03-26 | 2025-03-26 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| 8-K | 2025-01-27 | 2025-01-27 | View Filing |
| 8-K | 2025-01-06 | 2025-01-06 | View Filing |
| 8-K | 2024-12-09 | 2024-12-09 | View Filing |
| 8-K | 2024-12-04 | 2024-12-04 | View Filing |
| SC 13G/A | 2024-11-14 | 2024-11-14 | View Filing |
| 10-Q | 2024-11-07 | 2024-11-07 | View Filing |
| 4 | 2024-10-23 | 2024-10-23 | View Filing |
| EFFECT | 2024-09-13 | 2024-09-13 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| 4 | 2024-09-11 | 2024-09-11 | View Filing |
| CORRESP | 2024-09-11 | 2024-09-11 | View Filing |
| UPLOAD | 2024-09-06 | 2024-09-06 | View Filing |
| S-3 | 2024-08-30 | 2024-08-30 | View Filing |
| 10-Q | 2024-08-07 | 2024-08-07 | View Filing |
| 8-K | 2024-05-30 | 2024-05-30 | View Filing |
| 4 | 2024-05-29 | 2024-05-29 | View Filing |
| 4 | 2024-05-29 | 2024-05-29 | View Filing |
| 4 | 2024-05-29 | 2024-05-29 | View Filing |
| 4 | 2024-05-29 | 2024-05-29 | View Filing |
| 4 | 2024-05-29 | 2024-05-29 | View Filing |
| 4 | 2024-05-29 | 2024-05-29 | View Filing |
| 4 | 2024-05-29 | 2024-05-29 | View Filing |
| 10-Q | 2024-05-08 | 2024-05-08 | View Filing |
| DEFA14A | 2024-04-09 | 2024-04-09 | View Filing |
| DEF 14A | 2024-04-09 | 2024-04-09 | View Filing |
| 8-K | 2024-03-19 | 2024-03-19 | View Filing |
| 10-K | 2024-03-19 | 2024-03-19 | View Filing |
| SC 13G/A | 2024-03-06 | 2024-03-06 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Macd Rsi Composite Strategy | 17.39% | 1 | 1 | 1.32 | 1.85 | 24.63 |
| Neural Forcast | 13.46% | 0.97 | 20 | 0.65 | 0.48 | 20.7 |
| Pivot Points Strategy | 12.75% | 0.99 | 17 | 0.45 | 0.36 | 19.99 |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxx | x |
| xxxxxxxxxxxxxxxxx | xxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |